Cargando…

Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany

INTRODUCTION: In Germany, a 23-valent polysaccharide pneumococcal vaccine (PPSV23) is recommended for elderly (60+) and patients 16+ with chronic diseases not associated with immune suppression. For all other patients at risk, sequential immunization with a 13-valent pneumococcal conjugate vaccine (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuchenbecker, Ulrike, Chase, Daniela, Reichert, Anika, Schiffner-Rohe, Julia, Atwood, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5967715/ https://www.ncbi.nlm.nih.gov/pubmed/29795647 http://dx.doi.org/10.1371/journal.pone.0197905

Ejemplares similares

Pneumococcal vaccination rates in immunocompromised patients in Germany: A retrospective cohort study to assess sequential vaccination rates and changes over time
por: Sprenger, Ralf, et al.
Publicado: (2022)

Pneumococcal vaccination rates in immunocompromised patients—A cohort study based on claims data from more than 200,000 patients in Germany
por: Schmedt, Niklas, et al.
Publicado: (2019)

Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
por: Kuhlmann, Alexander, et al.
Publicado: (2012)

Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs
por: Horn, Matthias, et al.
Publicado: (2023)

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
por: Mangen, Marie-Josée J., et al.
Publicado: (2015)

Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China
por: Shen, Kunling, et al.
Publicado: (2018)

Efficacy of PPV23 in Preventing Pneumococcal Pneumonia in Adults at Increased Risk – A Systematic Review and Meta-Analysis
por: Schiffner-Rohe, Julia, et al.
Publicado: (2016)

Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study
por: Perniciaro, Stephanie, et al.
Publicado: (2021)

Cost-effectiveness of alternative strategies for use of 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian adults
por: Atwood, Mark, et al.
Publicado: (2018)

Correction to “Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study”
por: Perniciaro, Stephanie, et al.
Publicado: (2022)

Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany
por: van der Linden, Mark, et al.
Publicado: (2015)

Population-based incidence and mortality of community-acquired pneumonia in Germany
por: Theilacker, Christian, et al.
Publicado: (2021)

Response to Shami et al. ‘Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single dose vaccination strategy for adults in Hong Kong’ (Hum Vacc Immunother 2020)
por: Buchwald, Ulrike K., et al.
Publicado: (2020)

Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection
por: Marbaix, Sophie, et al.
Publicado: (2018)

Invasive Pneumococcal Disease in Refugee Children, Germany
por: Perniciaro, Stephanie, et al.
Publicado: (2018)

1439. The Cost-Effectiveness of Vaccinating Adults at Increased Risk of Pneumococcal Disease Against Pneumococcal Disease in The Netherlands
por: Rozenbaum, Mark
Publicado: (2018)

Retrospective Impact Analysis and Cost-Effectiveness of the Pneumococcal Conjugate Vaccine Infant Program in Australia
por: Perdrizet, Johnna, et al.
Publicado: (2021)

A longitudinal analysis of pneumococcal vaccine serotypes in pneumonia patients in Germany
por: Bahrs, Christina, et al.
Publicado: (2022)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
por: Kim, Hye-Young, et al.
Publicado: (2020)

Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom
por: Wilson, Michele, et al.
Publicado: (2023)

1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
por: Rozenbaum, Mark, et al.
Publicado: (2023)

Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany
por: Imöhl, Matthias, et al.
Publicado: (2015)

Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria
por: Pugh, Sarah J., et al.
Publicado: (2018)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia
por: Sundaram, Neisha, et al.
Publicado: (2017)

Impact of national pneumococcal vaccination program on invasive pneumococcal diseases in South Korea
por: Jung, Yeon Haw, et al.
Publicado: (2022)

Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
por: Polistena, Barbara, et al.
Publicado: (2022)

Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
por: Ghia, Canna J., et al.
Publicado: (2021)

Using LASSO Regression to Estimate the Population-Level Impact of Pneumococcal Conjugate Vaccines
por: Wong, Anabelle, et al.
Publicado: (2023)

Nasopharyngeal Carriage in Children After the Introduction of Generalized Infant Pneumococcal Conjugate Vaccine Immunization in Germany
por: Rose, Markus A., et al.
Publicado: (2021)

Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States
por: Chen, Jieling, et al.
Publicado: (2014)

Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea
por: Heo, Jung Yeon, et al.
Publicado: (2017)

Does Pneumococcal Vaccination Have an Effect on Hospital Costs?
por: Şimşek Veske, Nurdan, et al.
Publicado: (2023)

Estimation of Tinnitus-Related Socioeconomic Costs in Germany
por: Tziridis, Konstantin, et al.
Publicado: (2022)

Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
por: Ghia, Canna J., et al.
Publicado: (2021)

Population-based estimates of the effectiveness of pneumococcal vaccination in Australia
por: Gidding, Heather, et al.
Publicado: (2017)

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany
por: van der Linden, Mark, et al.
Publicado: (2016)

Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation
por: Kebede, Tayue Tateke, et al.
Publicado: (2019)

Low Pneumococcal Vaccination among Patients with Psoriasis in Germany: Results from Vac-Pso
por: Wellmann, Phoebe, et al.
Publicado: (2022)

Limited indirect effects of an infant pneumococcal vaccination program in an aging population
por: van der Linden, Mark, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sv7ikg04rlh22kv0fs7vafpa8b